IMTX Immatics N.V. IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1809196 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q2*2025-06-30 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 | 2021Q22021-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | 45.11M | — | — | 35.22M | — | 27.32M | 25.22M | 20.34M |
| SG&A expense | 12.78M | — | — | 10.13M | — | 9.36M | 8.68M | 8.27M |
| Operating income | -53.13M | — | — | -26.56M | — | -14.31M | -16.66M | -23.40M |
| Interest expense | 244,000 | — | — | 226,000 | — | 206,000 | 376,000 | 140,000 |
| Pretax income | -71.35M | 43.27M | -2.35M | -17.85M | -1.72M | -24.61M | -12.84M | -26.53M |
| Income tax | -1.00M | 2.52M | 2.95M | 140,000 | 518,000 | 0 | 1.15M | 0 |
| Net income | -70.35M | 40.76M | -5.30M | -17.99M | -2.24M | -24.61M | -13.98M | -26.53M |
| EPS (basic) | -0.58 | — | -0.05 | -0.17 | -0.02 | -0.32 | -0.22 | -0.42 |
| EPS (diluted) | -0.58 | — | -0.08 | -0.17 | -0.03 | -0.32 | -0.22 | -0.42 |
| Weighted avg. shares (diluted) | 121.55M | — | 110.30M | 103.07M | 105.93M | 77.31M | 64.92M | 62.91M |
| Balance sheet | ||||||||
| Cash & equivalents | 256.63M | 236.75M | 189.20M | 158.14M | 122.09M | 130.41M | 265.12M | 160.09M |
| Receivables | 1.96M | 5.86M | — | 2.81M | — | 330,000 | 961,000 | 718,000 |
| Current assets | 503.94M | 629.55M | — | 559.12M | — | 364.62M | 336.02M | 198.34M |
| PP&E, netmay include right-of-use assets (IFRS) | 46.31M | 50.38M | — | 50.29M | — | 27.19M | 11.27M | 8.75M |
| Intangibles | 1.60M | 1.63M | — | 1.61M | — | 1.66M | 1.31M | 1.26M |
| Total assets | 567.30M | 696.15M | 577.23M | 626.97M | 653.12M | 410.19M | 368.30M | 216.50M |
| Current liabilities | 57.25M | 67.99M | 128.91M | 149.55M | 149.10M | 124.31M | 113.99M | 93.93M |
| Total liabilities | 102.73M | 121.30M | 198.06M | 245.70M | 258.99M | 191.98M | 243.36M | 160.87M |
| Shareholders' equity | 464.57M | 574.84M | 379.17M | 381.26M | 394.13M | 218.21M | 124.94M | 55.63M |
| Cash flow statement | ||||||||
| Operating cash flow | — | -58.48M | -33.73M | -33.22M | -32.60M | — | — | — |
| Investing cash flow | — | -47.41M | 67.01M | 69.83M | -241.82M | — | — | — |
| Financing cash flow | — | 146.36M | -753,000 | -566,000 | 174.65M | — | — | — |
| Stock-based compensation | 4.14M | — | — | 4.31M | — | 5.51M | -5.56M | 7.96M |
Free plan shows the latest 8 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.